Carbocisteine is indicated for- Acute bronchitis, Chronic bronchitis, Bronchial asthma, Upper respiratory tract inflammation (pharyngitis, laryngitis), Cystic fibrosis Bronchiectasis, Pulmonary tuberculosis, Drainage in chronic sinusitis and pneumonia, Drainage in otitis media in children.
Cough expectorants & mucolytics
Carbocisteine reduces the viscosity of non-infected secretions from mucous cells in the respiratory tract. The mucolytic action is due to two mechanisms. It breaks the disulphide bonds which cross-link certain glycoprotein molecules present in the mucus and it also alters local ionic charges, both of which factors affect the viscosity of mucus. There is also evidence that it alters the composition of mucin secreted by the respiratory mucosa, decreasing the proportion of neutral glycopeptides and increasing the sialoglycopeptides.
Adult: Initially, 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves. Child: 2-5 year: 62.5-125 mg 4 times daily; 6-12 year 250 mg tid. Should be taken with food.
Neither hazardous nor therapeutically useful interactions have been reported.
Contraindicated in active peptic ulceration and in patients with hypersensitivity to the drug. No specific precaution is recommended but Carbocisteine should be used with caution in patients with a recent history of peptic ulcer and recurrent gastrointestinal bleeding.
Gastrointestinal discomfort, nausea, diarrhoea, gastrointestinal bleeding, palpitation, dizziness, headache, heartburn and skin rash may occur.
There is no information on the use of Carbocisteine during lactation. While there are no reports of teratogenic effects, the manufacturers do not recommend the use of Carbocisteine in the first trimester.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)